WEIGHT & METABOLISM / PEPTIDE CARD

Retatrutide

An investigational triple GIP, GLP-1, and glucagon receptor agonist in late-stage metabolic research.

PEPTIDE CARDRetatrutide

Reviewed
August 7, 2026

Human evidence

4/5 · Late-stage investigational

U.S. FDANot FDA approved

2026 WADANot specifically named

Inspect 3 sources

On this page

WHAT THE EVIDENCE SAYS

Retatrutide evidence summary.

Retatrutide has meaningful randomized human evidence, but it should not be described as an available approved alternative to semaglutide or tirzepatide.

Entity type
Peptide analogSource snapshot
August 7, 2026Record status
Sources attached

Do not overread this record

Promising trial results do not establish approval, product quality outside trials, or suitability for an individual.

01 / CLASSIFICATION

What is Retatrutide?

Entity typePeptide analog

Research categoryWeight & Metabolism

Known namesRetatrutide

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Incretin receptor agonists Goal: Weight & Metabolism Goal: Visceral Fat Research

02 / EVIDENCE

Retatrutide human and preclinical evidence.

HUMAN

4/5 · Late-stage investigational

Randomized Phase 2 trials are published and Phase 3 development is underway; the drug remains investigational.

PRECLINICAL

3/5 · Mechanism supported

Preclinical work supports triple-receptor pharmacology, but human trials are the decision-relevant evidence.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

Retatrutide FDA and sport status.

U.S. FDAInvestigational and not FDA approved; FDA states retatrutide cannot be used in compounding under federal law.

2026 WADANot specifically named in the 2026 List; athletes should verify current status before use.

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is Retatrutide being studied for?

01Obesity

02Type 2 diabetes

03Liver fat

04Cardiometabolic outcomes

05 / COMPARISONS

Compare Retatrutide.

Retatrutide vs TirzepatideAn investigational triple agonist compared with an approved dual agonist.Retatrutide vs SemaglutideInvestigational triple-receptor research compared with a mature GLP-1 evidence base.

06 / LATEST & DEFINING SOURCES

Retatrutide primary and official sources.

Human trial / 2023Triple-hormone-receptor agonist retatrutide for obesity — Phase 2

New England Journal of Medicine / PubMed

Registry / 2023Retatrutide Phase 2 obesity study

ClinicalTrials.gov

FDA / 2026FDA concerns with unapproved GLP-1 drugs used for weight loss

U.S. FDA

07 / QUESTIONS

Questions about Retatrutide.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for Retatrutide?

Retatrutide has meaningful randomized human evidence, but it should not be described as an available approved alternative to semaglutide or tirzepatide.

ResearchWhat is Retatrutide being studied for?

Current source-backed research areas include Obesity, Type 2 diabetes, Liver fat, Cardiometabolic outcomes. These areas describe investigation, not established personal benefit.

FDA statusIs Retatrutide FDA approved?

Current U.S. status for Retatrutide: Investigational and not FDA approved; FDA states retatrutide cannot be used in compounding under federal law.

Sport statusIs Retatrutide prohibited in sport?

Current sport-status snapshot for Retatrutide: Not specifically named in the 2026 List; athletes should verify current status before use.

Evidence limitsWhat are the main evidence limits for Retatrutide?

Promising trial results do not establish approval, product quality outside trials, or suitability for an individual.

Decision questionWhat is currently being studied for visceral fat?

The evidence depends on the population and the question. An approved indication, obesity treatment, and investigational research should not be collapsed into one list.

Decision questionIs retatrutide approved or available?

Retatrutide remains an investigational medicine. Published human evidence is not the same thing as regulatory approval or lawful retail availability.